PIMREG and lupus nephritis: To address this concept we developed a novel highly-specific Cat-S inhibitor and tested it in vivo in comparison to standard immunosuppression in a model of lupus-like immune complex-related vasculopathy of the kidney, i.e. lupus nephritis.